Sensus Healthcare Inc
NASDAQ:SRTS
Sensus Healthcare Inc
Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The company is headquartered in Boca Raton, Florida and currently employs 37 full-time employees. The company went IPO on 2016-06-03. The firm is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. The firm uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The firm incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100 Plus and SRT-100 Vision. SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. Its SRT-100 Plus offers remote diagnostics solutions, including operation tracking.
Sensus Healthcare, Inc. operates as a medical device company, which provides treatments for both oncological and non-oncological skin conditions. The company is headquartered in Boca Raton, Florida and currently employs 37 full-time employees. The company went IPO on 2016-06-03. The firm is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. The firm uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The firm incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100 Plus and SRT-100 Vision. SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. Its SRT-100 Plus offers remote diagnostics solutions, including operation tracking.
Revenue Drop: Sensus Healthcare reported Q4 2025 revenue of $4.9 million, down from $3.1 million in Q4 2024, and full-year 2025 revenue of $27.5 million versus $41.8 million in 2024, mainly due to fewer unit sales and lower sales to their largest customer.
New CPT Codes: SRT technology received dedicated CPT codes effective January 2026, providing reimbursement certainty and expected to drive broader adoption and growth.
Profitability Outlook: Management expects Q1 2026 revenue to exceed Q4 2025 and aims to achieve full-year profitability in 2026, even without contributions from their largest customer.
Customer Diversification: The company is less reliant on one large customer and is focusing on direct sales and expanding its customer base both in the U.S. and internationally.
International Expansion: Shipments to international markets, including China and other Asian countries, contributed six units in Q4, and international business remains a growth and margin focus.
Balance Sheet Strength: Sensus ended 2025 with $22.1 million in cash and no debt, giving them flexibility for 2026.
